AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05490888
Drug: PHIN-214 Subcutaneous injection
RxNorm normalized name: OCTINOXATE 7.5 g in 100 g / OXYBENZONE 6 g in 100 g / PADIMATE O 8 g in 100 g TOPICAL LIPSTICK [Phineas and Ferb Sun Smacker SPF 24 Berry Busted]
DrugBank: Oxybenzone (DB01428)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: subcutaneous injection(s) with PHIN-214 terlipressin derivative
Trial: NCT06608472
Drug: N0877
RxNorm normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 1 tablet of N0877 and 1 tablet of Placebo of Benicar HCT®
Trial: NCT06608368
Drug: Test Dentifrice (Sensodyne Repair and Protect Original Mint)
RxNorm normalized name: mumps skin test antigen
DrugBank: Rice (DB10563)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dentifrice containing 5% w/w NovaMin (Calcium Sodium Phosphosilicate) and 1040 ppm fluoride as sodium fluoride.
Trial: NCT06608368
Drug: Positive Control Dentifrice (Sensodyne Fresh Mint)
RxNorm normalized name: sodium fluoride
DrugBank: Rice (DB10563)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dentifrice containing 5% w/w KNO3 and 1150 ppm fluoride as sodium fluoride.
Trial: NCT06608368
Drug: Reference Dentifrice (Crest Cavity Protection Regular)
RxNorm normalized name: stannous fluoride
DrugBank: Rice (DB10563)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dentifrice containing 1100 ppm fluoride as sodium fluoride.
Trial: NCT05891561
Drug: Pertuzumab
RxNorm normalized name: Pertuzumab
DrugBank: Pertuzumab (DB06366)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 4 cycles of taxane, pertuzumab, trastuzumab
Trial: NCT06617832
Drug: Active drug for acute migraine treatment
RxNorm normalized name: activated charcoal Powder for Oral Suspension
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose of Sumatriptan 100 mg, which is used as an acute treatment for episodic migraine
Trial: NCT06682169
Drug: Imatinib
RxNorm normalized name: Imatinib
DrugBank: Imatinib (DB00619)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Imatinib tyrosine kinase inhibitor is a small molecule protein kinase inhibitor that has the ability to block one or more protein kinases. Clinically used for the treatment of chronic myeloid leukemia and malignant gastrointestinal stromal tumors.
Trial: NCT06682169
Drug: Mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Metoprolol ester is an organic compound mainly used as an immunosuppressant
Trial: NCT06682169
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab activates antibody dependent cell-mediated phagocytosis and complement dependent cytotoxicity by binding to cluster of differentiation 20 (CD20) antigen, clearing malignant B cells expressing CD20 and achieving therapeutic goals.
Trial: NCT04895137
Drug: mFOLFOX6+Bevacizumab+PD-1 monoclonal antibody treatment combinations
RxNorm normalized name: Anti-PD-1 monoclonal antibody MGA012
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: mFOLFOX6+ Bevacizumab+PD-1 monoclonal antibody treatment combinations in patients with local advanced microsatellite stability colorectal cancer
Trial: NCT06626711
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol as a part of total venous anesthesia
Trial: NCT06626711
Drug: Sevoflurane
RxNorm normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sevoflurane as a part of intravenous anesthesia
Trial: NCT06690814
Drug: Savlon antiseptic cream (cetrimide with chlorhexidine digluconate)
RxNorm normalized name: Listerine Antiseptic
DrugBank: Thymol (DB02513)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Common over the counter antiseptic cream
Trial: NCT05907395
Drug: PF-07293893
RxNorm normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-07293893 will be prepared as an oral suspension given in escalating single doses to be determined.
Trial: NCT06071767
Drug: Vesatolimod (VES)
RxNorm normalized name: colloidal oatmeal
DrugBank: Vesatolimod (DB12687)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VES 6 mg administered orally once every 2 weeks for two doses, then VES 8 mg once every 2 weeks for 8 doses. Dose escalation may be held or the 8 mg dose may be reduced for intolerability for weeks 6 through 24.
Trial: NCT06071767
Drug: GS-5423
RxNorm normalized name: GS 9137
DrugBank: Elvitegravir (DB09101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered via intravenous (IV) infusion at week 7
Trial: NCT06071767
Drug: GS-2872
RxNorm normalized name: GS 9137
DrugBank: Elvitegravir (DB09101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered via IV infusion at week 7
Trial: NCT05334368
Drug: Depemokimab
RxNorm normalized name: Depemokimab
DrugBank: Depemokimab (DB18846)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Depemokimab will be administered.
Trial: NCT06708741
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose oral vitamin D supplementation (50,000 IU/once per month)
Trial: NCT06709313
Drug: Chromium
RxNorm normalized name: Chromium
DrugBank: Chromium (DB11136)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants in the experimental group will receive oral chromium supplementation, the dosage of which is determined based on previous studies(200 mcg daily) taking into account safety and efficacy considerations. The supplementation will commence for 45 days following the injection.
Trial: NCT06708858
Drug: Surufatinib
RxNorm normalized name: Surufatinib
DrugBank: Surufatinib (DB15106)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200mg，qd，po
Trial: NCT06708858
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1000mg/ m2, IV，d1，8，q3w
Trial: NCT06708858
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 25mg/m2，IV，d1，8，q3w
Trial: NCT06708858
Drug: Durvalumab
RxNorm normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 1500mg，IV，d1，q3w
Trial: NCT06708858
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 200mg，IV，d1，q3w
Trial: NCT05843838
Drug: Heavy Bupivacaine for spinal anesthesia
RxNorm normalized name: bupivacaine hydrochloride Injectable Solution [Marcain Heavy]
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Routine clinical heavy bupivacaine doses
Trial: NCT05442190
Drug: Hypericin
RxNorm normalized name: Hypericin
DrugBank: Hypericin (DB13014)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SGX302 is synthetic hypericin formulated as a 0.25% hypericin ointment or gel.
Trial: NCT05502341
Drug: Bictegravir
RxNorm normalized name: Bictegravir
DrugBank: Bictegravir (DB11799)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tablets administered orally without regard to food
Trial: NCT05502341
Drug: Lenacapavir
RxNorm normalized name: Lenacapavir
DrugBank: Lenacapavir (DB15673)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets administered orally without regard to food
Trial: NCT05730777
Drug: Bifidobacterium Bifidum Oral Capsule
RxNorm normalized name: Bifidobacterium Bifidum Oral Capsule
DrugBank: Bifidobacterium bifidum (DB16538)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bifidobacterium Bifidum Oral Capsule for 6 months in addition to conventional treatment
Trial: NCT05730777
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients in the control group will receive conventional antitumor treatment only.
Trial: NCT05730777
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients in the control group will receive conventional antitumor treatment only.
Trial: NCT05957367
Drug: Ripretinib
RxNorm normalized name: Ripretinib
DrugBank: Ripretinib (DB14840)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Oral Tablet Formulation
Trial: NCT05730777
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients in the control group will receive conventional antitumor treatment only.
Trial: NCT05730777
Drug: Atlizumab
RxNorm normalized name: Atlizumab
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients in the control group will receive conventional antitumor treatment only.
Trial: NCT06199037
Drug: SHR-1707
RxNorm normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 cohort of Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease patients will receive SHR-1707 injection
Trial: NCT04797000
Drug: Eltrombopag
RxNorm normalized name: Eltrombopag
DrugBank: Eltrombopag (DB06210)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Eltrombopag comes in 12.5 mg \& 25 mg tablets and is taken orally once per day (QD)
Trial: NCT04493333
Drug: Vaginal Dehydroepiandrosterone
RxNorm normalized name: DEHYDROEPIANDROSTERONE
DrugBank: Prasterone (DB01708)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: This is a vaginally administered suppository steroid indicated for the treatment of moderate to severe dyspareunia, a frequent symptom of vulvovaginal atrophy due to menopause or genitourinary syndrome of menopause.
Trial: NCT06431373
Drug: Brepocitinib PO QD
RxNorm normalized name: Abrocitinib
DrugBank: Abrocitinib (DB14973)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Brepocitinib PO QD
Trial: NCT04713657
Drug: Propranolol Hydrochloride
RxNorm normalized name: Propranolol Hydrochloride
DrugBank: Propranolol (DB00571)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: For patients who are randomized to receive propranolol, The target dose for this study will be 4 mg/kg/day divided in 4 doses. The first dose will be given in the Pediatric Clinical and Translational Research Center (PCTRC) at 1mg/kg. Parents will administer propranolol (1 mg/kg po x 4 doses per day). Parents will be instructed to administer propranolol with feeding or soon after feeding, but not before feeding. families will also be given instructions for regarding 15N-thymidine dosing frequency and interval and provided with a log sheet to record administered and missed doses of propranolol and 15N-thymidine.
Trial: NCT04868409
Drug: Suxamethonium
RxNorm normalized name: Suxamethonium
DrugBank: Succinylcholine (DB00202)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 mg/kg for tracheal intubation after 60 seconds
Trial: NCT04868409
Drug: Rocuronium
RxNorm normalized name: Rocuronium
DrugBank: Rocuronium (DB00728)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 mg/kg for tracheal intubation after 60 seconds
Trial: NCT00939705
Drug: topiramate
RxNorm normalized name: Topiramate
DrugBank: Topiramate (DB00273)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Topiramate (brand name Topamax) is an anticonvulsant (antiepilepsy) drug. IUPAC name 2,3:4,5-Bis-O-(1-methylethylidene)-beta-D-fructopyranose sulfamate
Trial: NCT04234191
Drug: Buprenorphine/naloxone
RxNorm normalized name: BUPRENORPHINE/NALOXONE
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Buprenorphine/naloxone is an opioid agonist treatment for opioid use disorder. It is administered via sublingual tablet form.
Trial: NCT04234191
Drug: Hydromorphone
RxNorm normalized name: Hydromorphone
DrugBank: Hydromorphone (DB00327)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydromorphone is an opioid used for managing pain, craving, and withdrawal. It is administered orally via tablet or liquid form; or administered intravenously, subcutaneously, or intramuscularly via liquid form.
Trial: NCT05108922
Drug: Donanemab
RxNorm normalized name: Donanemab
DrugBank: Donanemab (DB16647)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received 700 milligram (mg) donanemab administered by intravenous (IV) infusion every 4 weeks (Q4W) for first three doses and then 1400 mg IV Q4W.
Trial: NCT05108922
Drug: Aducanumab
RxNorm normalized name: Aducanumab
DrugBank: Aducanumab (DB12274)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants received aducanumab administered by IV infusion per US label (prescribing information/routine clinical practice).
Trial: NCT06531291
Drug: Surufatinib
RxNorm normalized name: Surufatinib
DrugBank: Surufatinib (DB15106)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg, po, qd, q3w
Trial: NCT06531291
Drug: Serplulimab
RxNorm normalized name: Serplulimab
DrugBank: Serplulimab (DB17451)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg, iv, d1, q3w
Trial: NCT06143553
Drug: Paclitaxel Polymeric Micelles for Injection
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subjects are given 300 mg/m2 of Paclitaxel Polymeric Micelles for Injection without special infusion device,intravenously administrated for ≥ 3 hours.Three weeks constituted one course of treatment.
Trial: NCT06143553
Drug: Eribulin Mesilate injection
RxNorm normalized name: Eribulin Mesylate
DrugBank: Eribulin (DB08871)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Subjects are given 1.4 mg/m2 of Eribulin Mesilate injection on days 1 and 8 of the 21-day cycle.
Trial: NCT06143553
Drug: Gemcitabine Hydrochloride for Injection
RxNorm normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Subjects are given 800-1200mg/m2 of Gemcitabine Hydrochloride for Injection on days 1, 8 and 15 of the 28-day cycle.
Trial: NCT06143553
Drug: Vinorelbine Tartrate Injection
RxNorm normalized name: Vinorelbine Tartrate
DrugBank: Vinorelbine (DB00361)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects are given 25mg/m2 of Vinorelbine Tartrate Injection every first day of the week.
Trial: NCT06143553
Drug: Paclitaxel (albumin-bound)
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subjects are given 260mg/m2 of Paclitaxel (albumin-bound) on day 1 of the 21-day cycle,intravenous administration for more than 30 minutes.
Trial: NCT05831891
Drug: Fruquintinib combined with Serplulimab
DrugBank: Fruquintinib (DB11679)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fruquintinib 5mg, qd, 2w on/1w off and Serplulimab 4.5mg/kg, IV drip, d1, q3w
Trial: NCT03752203
Drug: Sodium Fluorescein
RxNorm normalized name: Fluorescein Sodium
DrugBank: Fluorescein (DB00693)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients enrolled in this study will receive 3 mg/kg sodium fluorescein following induction of anesthesia by administration into a peripheral venous line over 10 seconds
Trial: NCT06530537
Drug: Cilostazol
RxNorm normalized name: Cilostazol
DrugBank: Cilostazol (DB01166)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cilostazol 100mg twice daily
Trial: NCT06530537
Drug: Aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin 100mg once daily
Trial: NCT06402747
Drug: Clopidogrel
RxNorm normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Clopidogrel 75mg once daily
Trial: NCT06402747
Drug: Cilostazol
RxNorm normalized name: Cilostazol
DrugBank: Cilostazol (DB01166)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cilostazol 200mg per day
Trial: NCT04912011
Drug: Canrenoate Potassium
RxNorm normalized name: canrenoate potassium
DrugBank: Canrenoic acid (DB09015)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention: 200 mg of Canrenoate potassium in 100 ml 0,9% NaCl, intravenously twice a day for 7 days.
Trial: NCT04946461
Drug: Lisdexamfetamine Dimesylate
RxNorm normalized name: Lisdexamfetamine Dimesylate
DrugBank: Lisdexamfetamine (DB01255)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The dosage is set based on the recommendation of the practitioner. Lisdexamphetamine is only administered once a day.
Trial: NCT05712876
Drug: CK-0045
RxNorm normalized name: chlorhexidine
DrugBank: Chlorhexidine (DB00878)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interleukin-22 agonist
Trial: NCT04837092
Drug: FR104
RxNorm normalized name: Foralumab
DrugBank: Foralumab (DB16170)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FR104 treatment administration at day 0, day 14 then every 28 days until month 12
Trial: NCT06273540
Drug: STP7 (mavoglurant) or Placebo
RxNorm normalized name: INV-CSP #2002 METFORMIN OR PLACEBO
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: STP7 (mavoglurant) or Placebo twice a day (BID) from Days 3 to 9 according to the following dosing schedule: Day 3: 50 mg BID; Day 4: 100 mg BID; Days 5-9: 200 mg BID, and will take only the morning dose of STP7 (200 mg) on Day 10.~Cocaine / Saline~Participants will undergo cocaine/saline i.v. challenge sessions according to the schedule and doses:~* Screening (Session 1, Day -2): 20 mg cocaine, followed by a saline infusion, followed by 40 mg cocaine~* Baseline (Session 2, Day 1): saline or 20 mg cocaine followed by either 20 mg cocaine or saline.~* Baseline (Session 3, Day 2): saline or 40 mg cocaine followed by either 40 mg cocaine or saline.~* Treatment (Session 4, Day 9): saline or 20 mg cocaine followed by either 20 mg cocaine or saline.~* Treatment (Session 5, Day 10): saline or 40 mg cocaine followed by either 40 mg cocaine or saline.
Trial: NCT05128929
Drug: Hymecromone (H01)
RxNorm normalized name: hymecromone
DrugBank: Hymecromone (DB07118)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 mg oral H01 two times a day (total dose: 1600 mg/day).
Trial: NCT05255653
Drug: Olaparib
RxNorm normalized name: Olaparib
DrugBank: Olaparib (DB09074)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 300 mg twice daily for one year
Trial: NCT05255653
Drug: Durvalumab
RxNorm normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 1500 mg intravenous once every 4 weeks for in total 1 year (13 cycles) starting within the first week of radiotherapy,
Trial: NCT05255653
Drug: Medroxyprogesterone Acetate
RxNorm normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral medroxyprogesterone acetate for two years
Trial: NCT05255653
Drug: Megestrol Acetate
RxNorm normalized name: Megestrol Acetate
DrugBank: Megestrol acetate (DB00351)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral medroxyprogesterone acetate for two years
Trial: NCT04476550
Drug: Filgrastim
RxNorm normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 5 days of daily sub-cutaneous administration of 10mcg/kg filgrastim
Trial: NCT04460937
Drug: Adavosertib
RxNorm normalized name: Adavosertib
DrugBank: Adavosertib (DB11740)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT06492005
Drug: PD-1 inhibitior
RxNorm normalized name: Anti-pd-1 checkpoint inhibitor pf-06801591
DrugBank: Sasanlimab (DB18849)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive intravenous (IV) infusion of PD-1 inhibitor as per protocol
Trial: NCT06136728
Drug: Dalfampridine 10 MG [Ampyra]
RxNorm normalized name: dalfampridine 10 MG [Ampyra]
DrugBank: Dalfampridine (DB06637)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dalfampridine (10 mg) every 12 hours for 6 weeks.
Trial: NCT05364099
Drug: Lidocaine 1% Injectable Solution
RxNorm normalized name: lidocaine 1% injectable solution
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2.5 ml of 1% Lidocaine will be administered via injection in suprascapular nerve in the suprascapular notch
Trial: NCT06392971
Drug: Deep-sea fish oil
RxNorm normalized name: Deep Sea
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Starting from radiotherapy, the whole course of prophylactic oral deep-sea fish oil should be taken at the recommended dosage of 1g po bid according to the instructions (the administration method is to take it with the drug, remove the film on the drug surface, slowly swallow it in a supine position, and make the liquid fully contact with the esophageal mucosa). If no acute radioactive esophagus was assessed during the course of treatment, the patient was administered orally until the end of radiotherapy. If the patient developed radioactive esophagitis during the course of treatment, the relevant outcome measures were recorded and used as the endpoint event of the phase I study. The end point for patients without acute radiation esophagitis was at the completion of radiation therapy.
Trial: NCT05364099
Drug: Triamcinolone Injection
RxNorm normalized name: triamcinolone Injection
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.5 ml 40mg/ml Triamcinolone will be administered via injection in suprascapular nerve in the suprascapular notch
Trial: NCT05559554
Drug: AK104 (before the change)
RxNorm normalized name: THE-630
DrugBank: THE-630 (DB16750)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose 1 and dose 2 in pilot study, and recommended dose in pivotal study.
Trial: NCT04950166
Drug: pegsitacianine
RxNorm normalized name: Pegsitacianine
DrugBank: Pegsitacianine (DB19098)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An intraoperative nanoparticle-based fluorescence imaging agent comprised of micelles covalently conjugated to indocyanine green (ICG).
Trial: NCT05896748
Drug: Cabotegravir - Injectable Suspension (CAB LA)
RxNorm normalized name: cabotegravir Injection
DrugBank: Cabotegravir (DB11751)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: It is a sterile white to slightly pink suspension containing 200 mg/mL of CAB as free acid for administration by intramuscular (IM) injection. Each vial is for single-dose use containing a withdrawable volume of 2.0 mL, and does not require dilution prior to administration. CAB LA is composed of cabotegravir free acid, polysorbate 20, polyethylene glycol 3350, mannitol, and water for injection.